From: Gary S. Gevisser
Sent: Friday,
December 13, 2002 9:43 AM
To: Devin Standard
Cc: rest
Subject: RE: clinical studies…
Devin, God
willing I will be there with you. Tell me how to get there. The clinical
studies, FDA approval in terms of importance are pale in comparison to whether
the folks in charge have “proper &
adequate” coverage, not just in terms of insurance which is less of a
concern to me today than in the past, but more so their “BUSchooling”, i.e. what “tail” do these
guys have hanging
from their behinds[1]?
With that
said, lay out for me the deal that is currently on the table, i.e. what do they
want specifically, i.e. how much of an investment, use of proceeds etc and how
long before we get our money out assuming they have done good in the past, i.e.
what history do they have of clean escapes, i.e. no skid marks…---… and what
are they prepared at this time to “gift” us in
getting them all over the world map?
I am
copying “Butch
Cassidy” who is probably right now putting his feet up on his desk with
nothing better to do than to think about all the different hyperlinks that are now attached to
pages 1-64[2] to mention little of how
things will balance
out in the end as we approach the other
side of the son,
thinking of which how do we get Jonathan into the write
gear so that he is not to be eaten by a beast, swimming
lessons first, wouldn’t you agree?
gg
From: Devin Standard
Sent: Thursday, December 12, 2002
10:25 AM
To: Gary S. Gevisser
Cc: rest
Subject: clinical studies…
Dear Gary:
Please read below. I believe the approach at solving the problem
sounds logical and potential feasible. I know you have expertise in the field.
I will be meeting these gentlemen (The inventor and the business partner) on
Monday afternoon at
It has been explained to me that this device has received FDA approval. I would like to verify those documents. My only personal concern, above and beyond the specific FDA approval, is that the sample size of the study seems quite small. At Colgate, when we did our clinical trials, we had a minimum N, or population size, was 300. Please let me know your thoughts on this too.
They are looking for investment and distribution. We will get an update on their current US and Asian distribution. If you believe, in your expert opinion, that the device is credible, I believe we could introduce it in a fairly rapid fashion to African and Asian NGO’s under the auspices of the WHO in order to help alleviate mass suffering in an economically efficient manner.
Talk to you soon.
Read below and get back to me please.
Regards,
Devin
Devin S.
Standard
President
QuasArk
America, Inc.
964 5th
Ave., Suites 231-235
San Diego,
Ca 92101
USA
Tel: 858 337 1802
Fax:619 544 0993
Devin@quasark.com
